Skip to main content
. 2021 Feb 4;13(3):3202–3217. doi: 10.18632/aging.202242

Figure 1.

Figure 1

Anti-proliferative effects of GV1001 on prostatic epithelial and stromal cells. (A) Prostatic epithelial cell lines, RWPE-1, WPE1-NA22, and stromal cell line WPMY-1 were treated with dihydrotestosterone (DHT, 25 nM) or GV1001 (GV, 100 μM). Cells were exposed to GV1001 1 h before DHT treatment (GV + DHT) or co-treated with both DHT and GV1001 (DHT + GV). After 48 h, proliferation was accessed in a CCK-8 assay (n=5). ***p<0.001, **p<0.01, *p<0.05. Data are expressed as the mean ± SD. (B, C) RWPE-1, WPE1-NA22, and WPMY-1 cells were co-treated with DHT (25 nM) and GV1001 (100 μM) for 48 h and cell cycle analyzed by flow cytometry after PI staining. Data are presented in a histogram (B) and a table (C). * = Significantly different from the control (p<0.01). § = Significantly different from the DHT group (p<0.05).